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ABSTRACT
Class IIa bacteriocins are potent antimicrobial peptides produced by lactic acid bacteria to
destroy competing microorganisms. The N-terminal domain of these peptides consists of a
conserved YGNGV sequence and a disulphide bond. The YGNGV motif is essential for activity,
whereas, the two cysteines involved in the disulphide bond can be replaced with hydrophobic
residues. The C-terminal region has variable sequences, and folds into a conserved amphipathic
α-helical structure. To elucidate the structure-activity relationship in the N-terminal domain of
these peptides, three analogues (1-3) of a class IIa bacteriocin, Leucocin A (LeuA), were
designed and synthesized by replacing the N-terminal -sheet residues of the native peptide with
shorter -turn motifs. Such replacement abolished the antibacterial activity in the analogues,
however, analogue 1 was able to competitively inhibit the activity of native LeuA. Native LeuA
(37-mer) was synthesized using native chemical ligation method in high yield.

Solution

conformation study using circular dichroism spectroscopy and molecular dynamics simulations
suggested that the C-terminal region of analogue 1 adopts helical folding as found in LeuA,
while the N-terminal region did not fold into -sheet conformation. These structure-activity
studies highlight the role of proper folding and complete sequence in the activity of class IIa
bacteriocins.

Keywords: Antimicrobial peptide; Class IIa bacteriocins; Leucocin A (LeuA); Solid phase
peptide synthesis; Native chemical ligation; Antimicrobial activity; Solution conformation;
Structure-activity relationships
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1. Introduction
Bacteriocins are potent antimicrobial peptides with a potential in a variety of applications
such as food preservation, replacement of conventional antibiotics, and treatment of bacterial
multiple-drug-resistance.1-3 Bacteriocins derived from lactic acid bacteria are produced as a part
of their self defense mechanism to destroy competing microorganisms.4 Bacteriocins like class I
nisin and class IIa pediocin PA-1 are currently used for food preservation and their potential in
medical applications is being explored.1 Class IIa bacteriocins are unmodified cationic peptides
ranging from 37–48 residues that display activity against a variety of food pathogens, including
Listeria monocytogenes in the nanomolar range.2
Bacteriocins display potent activity by one or more of the proposed mechanisms of
actions. These peptides can (i) permeabilize the target cell membrane and reduce the proton
motive force of bacterial cells, (ii) induce lysis of the cell by activating autolysins
bind to the membrane bound receptor and cause pores in the cell wall.7,
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1, 5, 6

or (iii)

For class IIa

bacteriocins, it is becoming clear that peptides act by interacting with a specific receptor,
mannose phosphotransferase system (PTS) permease, on the target cell membrane and for this
peptide-receptor interaction folded conformation of the peptide is a key element. Comparison of
the amino acid sequence of class IIa bacteriocins shows that these peptides consist of a highly
conserved hydrophilic and charged N-terminal region harboring the consensus YGNGV
sequence and a disulfide bond. The C-terminal region is hydrophobic with a more variable
sequence. In contrast, the three dimensional solution structures of several class IIa bacteriocins
show that N-terminus region folds into different conformations, such as anti-parallel β-sheet or
coiled structure, and the C-terminal region maintains a conserved amphipathic α-helical
structure.9-11 The C-terminal helical region imparts target specificity and likely interacts with the
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target cell membrane bound receptor, whereas the positively charged N-terminal region interacts
with the cell surface by electrostatic interaction.12-14
Leucocin A (LeuA) is a 37 residue class IIa bacteriocin from Leuconostoc gelidium.15 A
series of experiments conducted by Fleury et al.16 to elucidate structure activity relationship
(SAR) of LeuA show that N-terminal YGNGV sequence and C-terminal tryptophan are essential
for activity. The N-terminal of LeuA (residues 2-16) consists of a three stranded anti-parallel βsheet which is stabilized by the disulphide bond between residues 9 and 14, and C-terminal
residues Trp18-Ala30 form an amphipathic -helix. (Figure 1a).9, 17 The conserved disulphide
bond between two cysteines maintains the correct geometry of other residues in the sequence and
this geometry is essential for its activity.18 Studies conducted by Derksen et al.18 confirmed that
the disulphide bond only contributes to maintain correct geometry in the molecule but does not
bind to the receptor on the bacterial cell membrane. The authors substituted the disulphide bond
with carbocyclic rings without losing activity while maintaining flexibility and geometry in the
synthetic LeuA. More recently it was shown that the replacement of the two Cys residues in the
N-terminal region of LeuA with hydrophobic residues such as Phe, Nva (Norvaline), AllylGly
yields a fully active analogue.19 On the other hand, substitution of the Cys with Ser residues in
LeuA made the peptide inactive. These results suggests that although the disulfide bond is
conserved among class IIa bacteriocins, it can be replaced with residues which can induce
similar geometry in the molecule without losing its antibacterial activity.
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W18

(c)
Peptide

Sequencea

Charge

LeuA
1
2
3

KYYGNGVHCTKSGCSVNWGEAFSAGVHRLANGGNGFW
KYYGNGVH--KP---VNWGEAFSAGVHRLANGGNGFW
KYYGNGVH--KSG---NWGEAFSAGVHRLANGGNGFW
KYYGNGVH--KPNG---WGEAFSAGVHRLANGGNGFW

+2
+2
+2
+2

No. of
residues
37
32
32
32

a

For analogues 1-3, residues in black are the same as in the native LeuA sequence,
green represents mutations, and – stands for deleted residue.
Figure 1. (a) NMR solution structure of native LeuA (PDB code: 1CW6)9 in 90% TFE. (b)
Schematic of the designed LeuA analogues depicting the replacement of a portion of N-terminal
-sheet region from LeuA with a smaller sequence. (c) Amino acid sequences of native LeuA
and peptide analogues studied herein.

We hypothesized that analogues of LeuA can be designed by replacing a portion of the
N-terminal -sheet region (Cys9-Ser15) with a smaller -turn. To validate this and study the
SAR of LeuA, three analogues (1-3) of LeuA were designed and synthesized by manipulating
the N-terminal region of the native LeuA (Figure 1). LeuA was synthesized as a control
5

employing native chemical ligation (NCL) of two smaller fragments of LeuA. The antimicrobial
activity of analogues and LeuA was evaluated against two indicator strains, Carnobacterium
divergens and Listeria monocytogenes. In general the analogues did not show any activity
whereas synthetic LeuA was highly active. Interestingly, analogue 1 was able to competitively
inhibit the activity of LeuA.

Solution conformation study using circular dichroism (CD)

spectroscopy suggested that only analogue 1 most likely adopts similar helical folding as LeuA.
Further, molecular dynamics (MD) simulations of 1 revealed that the C-terminal region folds
into a well-defined -helix, however, the N-terminal region does not form a -sheet structure
like the native LeuA emphasizing the role of proper folding in the activity of class IIa
bacteriocins.

2. Results and discussion
2.1 Design of LeuA Analogues
As mentioned above, the N-terminal region of LeuA mainly interacts with electrostatic
interaction with the target cell membrane. Therefore, the exact role of folded conformation in
the N-terminal region of class IIa bacteriocins is not clear. We designed three analogues of
LeuA by replacing the N-terminal -strand residues ranging from Cys9-Asn17 with smaller turn sequences (Figure 1). The analogues were 32-residue long, five residues less compared to
the native LeuA. Lys11 was kept in all the analogues to maintain the overall charge of +2. The
-strand residues Cys9-Thr10 and Gly13-Ser15 were deleted in analogue 1, and SerPro
mutation was introduced to increase the conformational stability of the -turn. Proline has a
unique restricted  angle that allows it to be entropically favourable at turn positions.20 In
analogue 2, the -turn sequence Lys-Ser-Gly (KSG) from the native LeuA was maintained
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whereas, in analogue 3, the -turn was substituted with another -turn motif, a conserved
tripeptide sequence Pro-Asx-Gly.21

2.2 Synthesis of LeuA and Analogues
Peptide analogues 1-3 were synthesized on 2-chlorotrityl chloride resin using Fmoc solidphase peptide synthesis.22 Crude peptides were purified using semi-preparative reversed-phase
HPLC prior to characterization by MALDI-TOF mass spectrometry. All peptide analogues were
purified up to >95% purity as shown by analytical RP-HPLC and mass spectrometry (Figure S1,
SI), and were obtained with an overall yield of 15-30%.
LeuA (37-mer) is a fairly hydrophobic peptide that gives rise to several truncated
sequences during stepwise linear synthesis. We attempted to establish a NCL method23-24 for
LeuA which allows synthesis of two smaller fragments that are ligated to give the complete
product.

NCL method leads to high purity, higher yields, low racemisation, low

aggregation/truncation of peptide, and allows synthesis of larger peptides. Therefore, it is a
promising alternative for the synthesis of LeuA and similar peptides. In order to perform NCL
reaction of two fragments, the first fragment should have C-terminal thioester and the other
fragment should have N-terminal cysteine residue. In general, the fragments are chosen based on
the presence of cysteine residue somewhere in the middle of the sequence. However this is not a
prerequisite as other residues, such as Alanine, can also be chosen at the fragmentation point.23
After NCL was first reported by Dawson et al,24 a number of peptides, protein, and enzymes
have been synthesized using this strategy.25
For the synthesis of LeuA using NCL, Cys14 was chosen as the potential ligation site
giving rise to two fragments, 13-residue fragment 1 (1-13) and 24-residue fragment 2 (14-37)

7

(Figure 2a). The NCL reaction is initiated by a chemo selective nucleophilic attack of the thiol
of Cys (N-terminal) of unprotected peptide fragment 2 on the C-terminal thioester moiety of

(a)

(b)

Figure 2. (a) Protocol for the synthesis of LeuA using NCL method. (b) Progress of the NCL
reaction monitored using RP-HPLC at time 0, 12 and 24 h. The two fragments, LeuA-13AA
(residues 1-13, F1) and LeuA-24AA (residues 14-37, F2) elute at 21 and 39 min, respectively,
whereas, the ligated product LeuA (residues 1-37) elutes at 26 min. The NCL reaction was
complete in 24 h.
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unprotected peptide fragment 1. This reaction is followed by rapid spontaneous rearrangement,
through an S-N acyl shift, giving rise to a ligated product.
The 13-residue fragment 1 (thioester) was synthesized using two different protocols as
shown in Figure S2. First method utilizes sulfonamide safety-catch resin for the thioester
synthesis26, 27 whereas the second method employs thioesterfication of the peptide synthesized
using 2-chlorotrityl resin.28 For the synthesis using sulfonamide safety catch resin, first amino
acid Fmoc-Gly (activation with PyBOP) was coupled manually to the 4-sulfamylbutyryl AM
resin followed by assembly of the remaining amino acids on automated synthesizer. After
complete peptide sequence, activation of the sulfonamide with iodoacetonitrile and displacement
with the thiol nucleophile ethyl-3-mercaptopropionate produced the protected thioester peptide.
LeuA 1-13 thioester (Fragment 1) was obtained after side chain deprotection using a mixture
containing TFA, TIS and water. Typical yield of the HPLC purified fragment 1 synthesized
using 4-sulfamylbutyryl AM resin was 21 mg (7% based on 0.2 mmol scale). Fragment 1 was
characterized by RP-HPLC and MALDI-TOF mass spectrometry. For the second method, the
peptide (1-13) was synthesized on 2-chlorotrityl resin. After cleavage from the resin with 1%
TFA, peptide with C-terminal carboxylate was obtained which was converted into thioester by
reaction with DIC, HOBt, DIPEA, and ethyl 3-mercatopropionate.

Finally, the side chain

protections and N-terminal Boc was removed as done for the first method. The second method
gave higher yield (100 mg, 33% based on 0.2 mmol scale) of the pure thioester fragment 1.
Fragment 2, 24-residue (14-37), was synthesized a 0.2 mmole scale on 2-chloro trityl
chloride resin following stepwise SPPS. After purification using RP-HPLC, fragment 2 was
obtained with an overall yield of 270 mg (55% based on 0.2 mmol scale) and purity greater than
95%. Next, the two fragments, fragment 1 thioester (4 mol) and fragment 2 (4 mol), were
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ligated in phosphate buffer (pH 7.6) containing 6 M GnHCl and thiophenol (4%)/ benzyl
mecaptan (4%) as catalysts.29 The reaction was monitored at different time intervals (0, 12 h, 24
h) by RP-HPLC. As shown in Figure 2b, the ligation was completed in 24 h, after which the
resultant ligated product was purified using semi-preparative RP-HPLC.

The presence of

thiophenol with excess with 3-mercaptopropionic acid ethyl ester significantly enhanced the
ligation reaction rate through nucleophilic catalysis.30 The pure peptide was characterized by
RP-HPLC and MALDI-TOF mass spectrometry (Figure S3). The yield of the chemical ligation
reaction to give pure peptide in the reduced form was 95-98% (14 mg).
The overall yield of the purified reduced LeuA was 0.06 mmol (30%) on a 0.2 mmol
scale synthesis. Oxidative folding or disulfide bond formation of the reduced peptide (14 mg)
was carried out to give 9.5 mg of oxidized LeuA peptide with an overall yield of 21% based on
0.2 mmol scale synthesis.
We also attempted the stepwise SPPS of LeuA using Cl-trityl resin and the overall yield
of LeuA obtained was 4.2%. In addition, others have attempted synthesis of Leu A using
specialized resins such as polyamide/kieselguhr resin with an overall yield 16%.16 Syntheses of
several unnatural analogues of LeuA, such as ent-LeuA and carba-LeuA and diallyl-LeuA have
been reported,18, 31, 32 and the overall yield for the analogues has been low, such for ent-LeuA
the yield was 6% using Wang resin as a solid support.31 The NCL method certainly seems more
promising for the synthesis of class IIa bacteriocins and analogues. Due to the hydrophobic
nature of these peptides, coupling amino acids after 20-residues to the solid support during
stepwise SPPS becomes very difficult. The elongated peptide tends to aggregate most likely due
to the hydrophobic C-terminal domain leading to the appearance of increased number of
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truncated peptides. To increase the yield and avoid loss of LeuA due to truncated peptides,
chemical ligation seems to be a better method for the synthesis of LeuA and analogues.

2.3 Antimicrobial Activity
The activity spectra of the LeuA analogues 1-3 were evaluated against two indicator
strains, Carnobacterium divergens and Listeria monocytogenes using liquid growth inhibition
assay as described previously.18 Synthetic LeuA (or LeuA) was used as a positive control. LeuA
displayed potent activity against C. divergens and L. monocytogenes with MIC values of 39 and
37 nM, respectively (Figure 3a). These MIC values were similar to the wild type peptide
reported previously.18, 22 However, none of the analogues (1-3) displayed any activity up to 200
M concentration. Next, the ability of analogues 1-3 to inhibit the antimicrobial activity of
LeuA was explored. Analogues 2 and 3 did not inhibit the activity of native LeuA, whereas, the
presence of analogue 1 led to significant inhibition of LeuA activity against C. divergens in a
dose-dependent manner (Figure 3b). At high concentration of analogue 1 (100 M), there was
almost complete inhibition of LeuA activity (OD 0.550.08). The optical density for the control
C. divergens sample, without LeuA and analogue 1, was 0.610.09. These results suggest that
the C-terminal helical region of analogue 1 may play an important role in mediating specific
interaction with the target cell membrane receptor.
The N-terminal sequence in analogue 1 that lacks the -sheet folding is likely responsible
for inactivity of 1. Chen et al. previously showed using N-terminal pediocin PA-1 fragments that
electrostatic interaction direct peptide binding to the target membrane.14 In our analogue design
(1-3), the charge of the N-terminal region was maintained (Table 1). Despite that analogues did
not show any activity suggesting that proper folding and/or complete sequence is essential for
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(a)

Wild type LeuA48

MICa (nM)
C. divergens
L. monocytogenes
35
35

Synthetic LeuA

39 ± 0.2

Peptide

37 ± 0.4

1
2
3
-, no activity detected up to 200 µM. Each assay against the two
strains was repeated at least three times.

(b)

Figure 3. (a) Antibacterial activity of LeuA and analogues against C. divergens and L.
monocytogenes. The MIC values represent peptide concentration that inhibited the growth by
50%. Data are represented as means ± standard errors of the means. The values are results of at
least three independent measurements. (b) Dose dependent decrease in antimicrobial activity of
LeuA in the presence of analogue 1 against C.divergens. Antimicrobial activity is expressed as
optical density at 600 nm ± standard deviation.

peptide bactericidal activity. In addition, it is important to note that in class IIa bacteriocins like
divercin V41, peptide fragment from the C-terminal domain (from residue 18 to 43) displays
activity.33 On the other hand, a change in the N-terminal domain in the native sequence while
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keeping the remaining sequence intact led to complete loss of activity, as observed for analogue
1. Likewise, fragment from C-terminal region of pediocin PA-1 (from residue 20 to 34) did not
display activity but were able to specifically inhibit the bactericidal activity of 44-residue
pediocin PA-1.13 Finally, it has been shown that long fragments (15-mer) from the N-terminal of
class IIa peptides such as pediocin PA-1, mesentericin Y105 and, enterocin CRL35, display
some antimicrobial activity, however, smaller fragments from the N-terminal are inactive.34

2.4 Structure-Activity Relationship
In order to understand the structural basis of inactivity of analogues, we next studied their
solution conformations using CD spectroscopy and MD simulations.
CD Spectroscopy. CD spectra of LeuA and analogues were obtained in 90% aqueous
TFE (pH~2.5) to compare the secondary structure of the peptides. TFE was used as a solvent as
class IIa bacteriocins form well-defined secondary structures in membrane mimicking solvents
like TFE, detergent micelles or vesicles, but are essentially unstructured in water.17, 22 Among
the three analogues, only analogue 1 displayed significant helical structure as indicated by the
appearance of a distinct negative band at 208 nm (= -11.4 x 103), a negative shoulder near 220
nm, and a positive band at 195 nm (Figure 4). In comparison, analogues 2 and 3 were much less
structured as observed from the CD spectra. The CD spectrum of 1 resembled that of LeuA
suggesting similar helical folding in the two peptides.22 Notably, the CD spectra of synthetic
LeuA shows similar peaks as observed previously for wild type LeuA22 with a negative band at
206 nm (θ = -10.5 x 103) and a negative shoulder near 220 nm (θ = -6.0 x 103) suggesting similar
folding pattern.
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Figure 4. Circular Dichroism (CD) spectra of synthetic LeuA and analogues 1, 2, and 3 in 90%
TFE (0.1% TFA final concentration, pH 2.5) at 200 M concentration.

Homology Modeling and MD Simulations. The secondary structure of analogue 1 was
further explored using MD simulations. First, a homology model of analogue 1 was constructed
using the 3D structure of native LeuA (PDB code-1CW6 9).22 Homology model was placed in
the middle of a cubic box (Figure 5a). The box was filled with solvent (TFE) followed by MD
simulations at two different temperatures, 298 K and 310 K. Snapshots were extracted after the
simulations at each nanosecond and were analysed using VMD software.35 Figure 5b shows the
overlay of several snapshots during simulation at 298 K. The peptide formed a stable structure
with a coiled N-terminal region and C-terminal folded into an -helical conformation. Clearly,
the N-terminal region of 1 was very different from the native LeuA. Next, the simulation was
conducted at an elevated temperature of 310 K. Peptide 1 showed the appearance of an Nterminal -sheet (Figure 5c); however, this conformation was present only for short duration
toward the end of the simulation (~ 9-10 ns). Overall, MD results suggest that the C-terminal
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region of analogue 1 fold more like native LeuA, whereas, the N-terminal region displays
marked differences from the native peptide.

(a)

(a)

(b)

(b)

(c)

(c)

Figure 5. (a) Initial setup of a simulation box with box size X, Y and Z = 6 nm for MD
simulation of analogue 1. TFE is rendered in blue, analogue 1 in yellow ribbon, and Na+ and Clions in magenta and blue, respectively. (b) Overlay of snapshots of 1 (9-10 ns) extracted from
simulation at 298 K. The superimposed images show that the peptide conformation was stable
with an N-terminal coil and C-terminal helix. (c) Snapshot of 1 extracted (~9 ns) from simulation
at 313 K.
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3. Conclusion
In conclusion, LeuA analogues (1-3) studied here support earlier investigations that the
C-terminal region is required for specificity and dictates the antimicrobial profile, whereas, the
N-terminal sequence is necessary for activity. Replacement of few N-terminal residues with
conservative substitutions is allowed as shown previously,19 however, the complete N-terminal
domain is required for activity. Further, we found that NCL is a better approach for the solid
phase synthesis of LeuA like peptides. NCL method gives high yield and is an efficient method
for obtaining large amounts of LeuA. The NCL method described here can be utilized in future
for the synthesis of other class IIa bacteriocins and library of analogues for performing
comprehensive SAR studies.

NCL method avoids unnecessary repeated synthesis of the

unaltered sequences in a peptide during analogues syntheses.

4. Experimental Section
4.1 Synthesis of Peptide Analogues
Synthesis of peptide analogues 1-3 was carried out on 1.0% DVB cross-linked
chlorotrityl resin (0.2 mmol, loading 1.05 mmol/g) following the standard Fmoc solid-phase
peptide chemistry with acid labile side chain protections (t-Bu, Boc, Trt) as described
previously.36 Peptides were synthesized using MPS 357 automated peptide synthesizer robot
(Advanced Chemtech Inc., USA). To assist the coupling of difficult residues (Asn, Ser, and for
all residues after position 10), increased coupling times were employed. Test cleavage was
performed at regular intervals (every 5 amino acids) by adding 50% TFA in DCM to a small
amount of resin followed by shaking for 30 min at room temperature. The complete peptide
sequences were released from support with concomitant removal of acid-labile side chain
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protecting groups using the same procedure as used for the test cleavages. The filtrate from the
cleavage reactions was combined with TFA washes (3x 2 min, 1 mL), and concentrated in
vacuum. Cold diethyl ether (~15 mL) was added to precipitate the crude cleaved peptide. After
trituration for 2 min, the peptides were collected upon centrifugation. The crude peptides were
dissolved in 20% aqueous isopropanol and purified on HPLC using a semi-preparative VYDAC
C8 RP-HPLC column (1 x 25 cm, 5 μm) with an isopropanol/water gradient in the presence of
0.05% TFA. The gradient used was 25-95% isopropanol/water in 45 minutes at a flow rate of
1.0 mL/min. Pure peptides obtained in 15-30% yield were characterized by analytical reversedphase HPLC and MALDI-TOF mass spectrometry (Figure S1, SI). The purity of the peptides
was verified to be 95% by reversed-phase chromatography. The pure lyophilized peptide
analogues were stored at -20 C under nitrogen.

4.2 Synthesis of LeuA
The synthesis of native LeuA was attempted using native chemical ligation of two
fragments, 13-mer N-terminal fragment 1 and 24-mer C-terminal fragment 2.

4.2.1. Synthesis of Fragment 1 Thioester
In order to obtain higher yield of the thioester for fragment 1, two methods were
attempted for the synthesis (Figure S2). The first method employed sulfonamide safety catch
resin, whereas the second method used 2-chlorotrityl resin. The synthesis of fragment 1 thioester
using Fmoc chemistry on sulfonamide safety catch resin (4-sulfamylbutyryl AM resin, 0.9
mmol/g, 0.2 mmol) followed procedure described by Ingenito et al.26 The first amino acid
glycine (1 mmol, 5 eq) was coupled manually to the resin using coupling agents PyBOP (1
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mmol) and iPr2EtN (0.75 mmol). The reaction mixture was agitated for 8 h at -20 C followed
by 8 hr at r.t. to get maximum loading of the first amino acid27. After deprotection of the first
amino acid using freshly prepared 20% piperidine in DMF, rest of the amino acids were coupled
using DIC/HOBt activation protocol on automated peptide synthesizer.
synthesis, coupling reactions were monitored using ninhydrin test.

During the entire

After completion of

synthesis, the full length peptide was released from resin with concomitant removal of acid-labile
side chain protecting groups and formation of C-terminal thioester. The resin was first treated
with DIPEA (2 mmol, 10 eq) and iodoacetonitrile (1.6 mmol, 8 eq) in NMP in dark for 24 h at
room temperature. Following this, the resin was washed and ethyl-3-mercaptopropionate (50 eq)
and sodium thiophenol (0.5 eq) in DMF were added to a final concentration of 1 M. The
reaction mixture was agitated for 24 h at r.t. The resin was filtered and washed with DMF (3 x 2
mL). The combined filtrate and washings were collected in flask, vacuum concentrated and
washed with cold anhydrous diethyl ether to remove traces of mercaptans. Finally, the amino
terminal Boc group and the side chain protecting groups were removed from the peptide by
addition of a cleavage cocktail (95:5:5 TFA/TIS/H2O) and the mixture were stirred at r.t. for 2.5
h. The solution was evaporated in vacuum and the residual oil was treated with cold anhydrous
ether (~15 mL). The resulting precipitate was collected by centrifugation and freeze dried.
Precipitate was dissolved in 20% acetonitrile/water and purified by semi-preparative RP-HPLC
to give pure fragment 1 thioester yield 7% (21 mg, 0.013 mmol). MALDI-TOF calcd for
fragment 1, [M+H]+ 1530.1; found 1530.3.
The second method employed 2-chlorotrityl resin (loading 1.6 mmol/g, 0.2 mmol) for the
preparation of fragment 1 thioester. The peptide assembly was achieved following procedure
described for the analogues except that the N-terminal lysine was Boc-protected. After peptide
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assembly, peptide was cleaved from the resin using 1% TFA/DCM (3 x 4 mL, each for 3 min).
The acidic supernatants were combined in reaction vessel containing DIPEA (6.65 mmol, 1160
L) to yield a final peptide concentration of 4 mM. To this solution, ethyl 3-mercatopropionate
(6 mmol, 30 eq), HOBt (4 mmol, 20 eq), DIC (4 mmol, 20 eq), and additional DIPEA (1.33
mmol, 230 L) were added. The mixture was stirred overnight and concentrated. The protected
peptide thioester was precipitated by multiple triturations with cold diethyl ether followed by
centrifugation. Deprotection of side chains and N-terminal Boc was carried out as described
above. The crude product was purified using semi-preperative RP-HPLC to give pure fragment
1 thioester with a 33% yield (100 mg, 0.065mmol). Calcd. [M+H]+ 1530.1, found 1530.7.

4.2.2. Synthesis of Fragment 2
Synthesis of 24-residue fragment 2, LeuA (14-37), was carried out on 2-chlorotrityl
chloride resin (0.2-mmol) as described for the analogues. After purification of the crude peptide
using RP-HPLC, pure fragment 2 was obtained with 55% yield.

MALDI-TOF calcd for

fragment 2, [M + H]+ 2536.1; found 2536.6.

4.2.3. Native Chemical Ligation
The chemical ligation of unprotected linear peptide fragments 1 and 2 was done
following literature protocol.29, 37 Fragment 1 (0.004 mmol, 6 mg) and fragment 2 (0.004 mmol,
10 mg) were dissolved in freshly degassed sodium phosphate buffer (0.2 M) containing
guanidine HCL, (6 M, pH 7.5), and the ligation reaction was started by addition of a mixture of
thiophenol (4%) and benzylmecaptan (4%). The solution was stirred at 25 °C for 24 hr under
argon at r.t. and monitored by semi-preparative RP-HPLC and MALDI-TOF MS. The ligation
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reaction was completed after 24 hr. The precipitate was collected, freeze dried, followed by
purification with RP-HPLC method and characterization. MALDI-TOF calcd for reduced linear
LeuA, [M+H]+ 3930.7; found [M+H]+ 3930.3; overall yield 30%. The pure peptide was
subjected to oxidative folding (disulfide formation) by air oxidation in freshly degassed Tris
buffer (50 mM, pH 8.4). Briefly, peptide (10.3 µmol, 41 mg) was dissolved in Tris buffer at a
concentration of 1 mg/mL, and 20% DMSO was added to the buffer to enhance peptide
solubility and oxidation. The solution was gently stirred in an open-air flask for 48 h, and the
reaction was monitored using Ellman test38 and mass spectrometry (Figure S3). Oxidized
peptide was subjected to RP-HPLC to obtain pure cyclized LeuA in 70% yield. MALDI-TOF
calcd [M+H]+ 3928.7, found [M+H]+ 3929.1. The overall yield of LeuA using NCL method was
21%.
Leu A was also prepared using Fmoc-SPPS on Cl-trityl resin where 37 amino acids were
added linearly followed by peptide cleavage from resin and oxidation (disulfide formation).
Using this method, the overall yield of cyclized LeuA after purification was 4.2%.

4.3 Antimicrobial Activity
Peptide stock solutions (25 µM) were prepared in methanol/water (1:3) and serial
dilutions were made as required. Peptide concentrations of the stock solutions was determined
by measuring UV absorbance at 280 nm following literature procedure.39 Antimicrobial activity
assay followed by determination of minimum inhibitory concentrations (MICs) were done using
the liquid growth inhibition assay in microtiter plates as described previously.36 The indicator
strains used were Carnobacterium divergens UAL9 (grown in APT broth at 25 C) and Listeria
monocytogenes ATCC 15313 (TSYBE, 37 C). The indicator strains were obtained from the
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culture collection of CanBiocin Inc. (Edmonton, Alberta, Canada). MICs were defined as the
peptide concentration that inhibited the growth of the indicator strain by 50%.

For the

competition experiments using the liquid growth inhibition assay, a range of concentrations of
analogue 1 (0-100 M) was incubated with indicator strain (C. divergens, diluted 1:100) in the
presence of LeuA (slightly above its MIC, 50 nM). The final volume of each well of the
microtiter plate was made 200 L with the culture medium. The microtiter plate culture was
incubated overnight at 25 ºC, after which the growth of the indicator strain was measured
spectrophotometrically at 600 nm using microtitre plate reader (TECAN, Männedorf,
Switzerland).

4.4 Characterization of Leu A analogues

4.4.1. CD Spectroscopy
CD spectra of LeuA analogues 1-3 and synthetic LeuA were obtained using an Olis CD
spectrometer (Georgia, USA) in a thermally controlled quartz cell with 0.02 cm path length over
196-250 nm. Peptide samples with a final concentration of 200 M were prepared in 2,2,2trifluoroethanol (90% TFE) containing 0.1% aqueous TFA (pH~2.5). The baseline scan was
performed by taking the buffer alone and subtracted from experimental readings. Data were
collected every 0.05 nm and were average of 6 scans. The normalized CD data was expressed in
units of molar ellipticity per residue (deg cm2 dmol-1) and plotted versus the wavelength.

4.4.2. Molecular Dynamic Simulations
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MD simulation of peptide analogue 1 was conducted using GROMCAS as described
previously.22, 40 BLAST 41 and FASTA 42 sequence alignment tools were used to search for other
similar sequences apart from LeuA. Analogue 1 displayed high sequence identity with LeuA
and the solution NMR structure of LeuA in TFE (PDB code 1CW6)9 was used to construct
homology model of 1 using the magic fit tool in the VMD-software.35 The homology model was
chosen as the starting structure for MD simulations using GROMACS MD simulation package
(GROMOS96 force field).43, 44 TFE was used to solvate the simulation box and simulations were
conducted in the NPT ensemble at 298 or 313 K using periodic boundary conditions. Weak
coupling of the peptide to a solvent bath of constant temperature was maintained using the
Berendsen thermostat 45 and pressure was controlled using the Berendsen algorithm at 1 bar with
a coupling constant 4 ps, using a compressibility of liquid TFE of 1.22 x 10-4 and 1.34 x 10-4 kJ-1
mol nm3 at 298 and 313 K, respectively.46 The electrostatic and van der Waals interactions were
truncated at a cutoff distance of 1.2 nm. The integration time step was 2 fs, and the coordinates
and velocities were saved every 2 ps. The LINCS algorithm was used to restrain all bond lengths.
A cubic box (6×6×6 nm3) was constructed and used to run the simulation. Parameters for TFE
solvent were prepared according to Fioroni et al.46 Homology model of analogue 1 was placed
in the centre of the box by replacing the TFE molecules equivalent to the peptide size. The Nterminal was positively charged (NH3+) and C-terminal was considered to be negatively charged
(COO-). In the sequence, residues Asp, Arg, Glu and Lys were charged and His residues were
kept neutral. Sufficient counter ions (Na+, Cl-) were added to make the system electro neutral
and to provide a final concentration of ~100 mM. Energy within the system was minimized
before MD simulation using 200 steps of the steepest descent energy minimization method in
order to relax any steric conflicts generated during the set-up. The equilibration of the analogue
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1-TFE system was achieved by performing a 3 ns MD run with positional restrain on the peptide
molecule. Following this, a full MD run of 10 ns was performed without any restraints at 298 K
followed by at 310 K. Snapshots of the peptides were extracted from 1-10 ns. Simulations were
analyzed using various GROMACS post processing routines.43 Swiss-Pdb Viewer 47 and VMD35
softwares were used to visualize, analyse and superimpose structures.
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